Press Releases Items Per Page 102550 News Category FinancialGeneral Year None20192018201720162015201420132012201120102009200820072006 Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium Feb 25, 2019 Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets Feb 21, 2019 Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium Feb 15, 2019 Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium Feb 11, 2019 ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics Jan 03, 2019 Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Dec 27, 2018 Nektar Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of Nektar's Oncology Programs Nov 14, 2018 Nektar Therapeutics Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 09, 2018 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2018 Nov 07, 2018 New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers Nov 06, 2018 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Current page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »